Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Dan and next week

<< Previous

Bullboard Posts

Next >>

Comment by Inthepezon Oct 26, 2021 7:55pm

322 Views

Post# 34052760

RE:RE:RE:RE:Dan and next week

Failure is a strong word. GI safety: excellent. Analgesia: excellent.
This liver enzyme elevation is a dosing issue.

MasterAlgae wrote: Nor is the fault of the CEO that the lead drug failed.
The CEO got a boat-load of after-tax money from the retail investor - that is a success, job done.
Most of us are not happy with the failure but that's the risk.

Forestview wrote: You should email him and vent your frustrations directly to him. Doing it here is pointless.

dan@antibethera.com

Layth1990 wrote: He still can save the company if he resigns